Native Cell Membrane Nanoparticles System
天然细胞膜纳米粒子系统
基本信息
- 批准号:10454882
- 负责人:
- 金额:$ 38.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:ATP phosphohydrolaseATP-Binding Cassette TransportersAddressAdoptedBacillus cereusBacteriaBiochemicalBiologyCell Membrane ProteinsCell membraneCellsCharacteristicsCryoelectron MicroscopyDataDetergentsEnvironmentEscherichia coliGoalsHomologous GeneHumanInsectaLaboratoriesLibrariesLipid BilayersLipidsListeria monocytogenesMaleic AnhydrideMammalian CellMembraneMembrane LipidsMembrane ProteinsMembrane Structure and FunctionMindModernizationMolecular WeightNPC1 geneNiemann-Pick DiseasesOrganismPharmaceutical PreparationsPlayPolymersPreparationProteinsProtocols documentationProton-Translocating ATPasesResearchResolutionRoleSaccharomyces cerevisiaeSensoryStructureStyrenesSystemTRP channelTestingTransmembrane DomainTryptophanWorkYeastsbasebiophysical analysiscell injurycopolymerdrug developmentdrug discoveryflexibilitymembrane activitymembrane modelnanodisknanoparticleparticleprotein structureprotocol developmentprototypescreeningstructural biology
项目摘要
SUMMARY
Membrane proteins play crucial roles in living organisms. Protein-lipid interactions are crucial for the
structural and functional integrity of membrane proteins. High-resolution of membrane protein structures
are in high-demand for both understanding their biology and structure-based drug discovery. It is often need
to extract membrane proteins from cell membranes for biochemical and biophysical study. Currently
detergents are predominantly used for membrane protein extraction. Detergents have significant drawbacks
in that they destroy lipid bilayer and remove important lipid molecules from membrane proteins. We are
developing a detergent-free native cell membrane nanoparticles system for membrane protein research. The
native cell membrane nanoparticles system is composed of three components: 1) Membrane active
polymers. 2) Protocols for preparation of native cell membrane nanoparticles. 3) Single-particles cryo-EM
analysis of the native cell membrane nanoparticles. We propose to develop a system that can be generally
applicable to both prokaryotic and eukaryotic membrane proteins. Specific Aim 1 focuses on construction
of membrane active polymer library and develop protocols for preparation of native cell membrane
nanoparticles using our selected model membrane proteins. We have developed four prototype membrane
active polymers, with the similar strategies we plan to expand the membrane active polymers using both
commercially available styrene maleic anhydride copolymers and polymers synthesized in laboratories.
Specific Ami 2 focuses on developing protocols for high-resolution structure determination of selected
prokaryotic model membrane proteins. Specific Aim 3 focuses on developing protocols for high-resolution
structures of selected eukaryotic model membrane proteins. The proposed research is significant because it
provides a revolutionary detergent-free approach for study membrane proteins in their local lipid
environment. As we have demonstrated in our preliminary data, we found the structural information of
protein-lipid interaction for membrane proteins is crucial for understanding the structure and function of
membrane proteins. This system might transform the membrane protein research field and have a great
impact for membrane protein structure based drug discovery and development.
概括
膜蛋白在生物体中起关键作用。蛋白 - 脂质相互作用对于
膜蛋白的结构和功能完整性。膜蛋白结构的高分辨率
高需求既了解它们的生物学和基于结构的药物发现。通常需要
从细胞膜中提取膜蛋白进行生化和生物物理研究。现在
洗涤剂主要用于膜蛋白提取。洗涤剂有明显的缺点
因为它们破坏了脂质双层并从膜蛋白中去除重要的脂质分子。我们是
开发用于膜蛋白研究的无洗涤剂天然细胞膜纳米颗粒系统。这
天然细胞膜纳米颗粒系统由三个组成部分组成:1)膜活动
聚合物。 2)制备天然细胞膜纳米颗粒的方案。 3)单粒子冷冻EM
天然细胞膜纳米颗粒的分析。我们建议开发一个可以通常的系统
适用于原核生物和真核膜蛋白。特定目标1专注于施工
膜活动聚合物库的库,并开发用于制备天然细胞膜的方案
使用我们选择的模型膜蛋白的纳米颗粒。我们已经开发了四个原型膜
活性聚合物,我们计划采用类似的策略来扩展膜活性聚合物
实验室合成的市售苯乙烯马利甲基酸酐共聚物和聚合物。
特定的AMI 2专注于开发用于高分辨率结构确定所选协议
原核模型膜蛋白。特定目标3专注于为高分辨率开发协议
选定的真核模型膜蛋白的结构。拟议的研究很重要,因为它
提供了一种无革命性的清洁剂方法,用于研究膜蛋白的本地脂质
环境。正如我们在初步数据中所证明的那样,我们发现了
膜蛋白的蛋白质脂质相互作用对于理解理解的结构和功能至关重要
膜蛋白。该系统可能会改变膜蛋白研究领域,并具有很好的
对基于膜蛋白结构的药物发现和发育的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Youzhong Guo其他文献
Youzhong Guo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Youzhong Guo', 18)}}的其他基金
Proposal for an Administrative Supplement for Equipment Purchases for NIGMS Awardees NOT-GM-22-017
NIGMS 获奖者设备采购行政补充提案 NOT-GM-22-017
- 批准号:
10645526 - 财政年份:2019
- 资助金额:
$ 38.26万 - 项目类别:
相似国自然基金
基于超声多模态评价技术探讨肝脏靶向递送ABCA1新策略在动脉粥样硬化防治中的应用
- 批准号:81871357
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
基于SIRT1-LXR通路的化合物E4023抗动脉粥样硬化的作用及机制研究
- 批准号:81703503
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
基于LXRα-SREBP1-ABCA1/G1信号通路的益气活血化痰方调脂抗动脉粥样硬化机制研究
- 批准号:81774088
- 批准年份:2017
- 资助金额:55.0 万元
- 项目类别:面上项目
肝脏X受体激动剂干预β淀粉样蛋白诱导的视网膜炎性反应的作用及机制
- 批准号:81670881
- 批准年份:2016
- 资助金额:51.0 万元
- 项目类别:面上项目
新型ABCA1上调剂E17241改善糖脂代谢紊乱的机制研究
- 批准号:81573482
- 批准年份:2015
- 资助金额:50.0 万元
- 项目类别:面上项目
相似海外基金
Inhibition or evasion of P-glycoprotein-mediated drug transport
抑制或逃避 P-糖蛋白介导的药物转运
- 批准号:
10568723 - 财政年份:2023
- 资助金额:
$ 38.26万 - 项目类别:
Characterization of MsbA inhibitors as potential antibiotic leads to treat carbapenem-resistant Enterobacteriaceae (CRE)
MsbA 抑制剂作为潜在抗生素的特性可用于治疗耐碳青霉烯类肠杆菌 (CRE)
- 批准号:
10242174 - 财政年份:2020
- 资助金额:
$ 38.26万 - 项目类别:
Characterization of MsbA inhibitors as potential antibiotic leads to treat carbapenem-resistant Enterobacteriaceae (CRE)
MsbA 抑制剂作为潜在抗生素的特性可用于治疗耐碳青霉烯类肠杆菌 (CRE)
- 批准号:
9978345 - 财政年份:2020
- 资助金额:
$ 38.26万 - 项目类别:
Probing adenylate kinase-dependent CFTR gating in vivo and as therapeutic target
体内探索腺苷酸激酶依赖性 CFTR 门控并作为治疗靶点
- 批准号:
9383695 - 财政年份:2017
- 资助金额:
$ 38.26万 - 项目类别: